Results 61 to 70 of about 3,724 (119)
Some of the next articles are maybe not open access.
Drugs, 2009
Granisetron is a highly selective serotonin 5-HT(3) receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. The transdermal granisetron system delivers continuous granisetron (3.1 mg/day) into the systemic circulation (via passive diffusion) for up to 7 days. In a large phase III trial in cancer patients receiving multi-day (
Sean T, Duggan, Monique P, Curran
openaire +2 more sources
Granisetron is a highly selective serotonin 5-HT(3) receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. The transdermal granisetron system delivers continuous granisetron (3.1 mg/day) into the systemic circulation (via passive diffusion) for up to 7 days. In a large phase III trial in cancer patients receiving multi-day (
Sean T, Duggan, Monique P, Curran
openaire +2 more sources
Drugs, 2009
*Oxybutynin inhibits contraction of the detrusor muscle in the overactive bladder by binding to muscarinic M(3) receptors and blocking acetylcholinergic activation. *The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. The transdermal route of administration avoids the extensive first-
Claudine M, Baldwin, Gillian M, Keating
openaire +2 more sources
*Oxybutynin inhibits contraction of the detrusor muscle in the overactive bladder by binding to muscarinic M(3) receptors and blocking acetylcholinergic activation. *The transdermal oxybutynin system, applied twice weekly, delivers continuous oxybutynin over a 96-hour patch wear period. The transdermal route of administration avoids the extensive first-
Claudine M, Baldwin, Gillian M, Keating
openaire +2 more sources
Drugs, 2003
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. At least satisfactory analgesia with minimal requirement for rescue medication (
Hannah C, Evans, Stephanie E, Easthope
openaire +2 more sources
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. At least satisfactory analgesia with minimal requirement for rescue medication (
Hannah C, Evans, Stephanie E, Easthope
openaire +2 more sources
Drugs, 1998
Nightly application of testosterone transdermal (TTD) system to nonscrotal sites in men with hypogonadism results in a 24-hour serum testosterone concentration profile which mimics the circadian pattern observed in healthy young men. The system also normalises dihydrotestosterone/testosterone and estradiol/testosterone ratios and reduces luteinising ...
K J, McClellan, K L, Goa
openaire +2 more sources
Nightly application of testosterone transdermal (TTD) system to nonscrotal sites in men with hypogonadism results in a 24-hour serum testosterone concentration profile which mimics the circadian pattern observed in healthy young men. The system also normalises dihydrotestosterone/testosterone and estradiol/testosterone ratios and reduces luteinising ...
K J, McClellan, K L, Goa
openaire +2 more sources
Annals of Pharmacotherapy, 1992
OBJECTIVE: To review the use of transdermal fentanyl for the treatment of moderate to severe chronic pain. The article provides background on the pharmacology and pharmacokinetics of the drug, as well as the properties of the transdermal system.
L Y, Yee, J R, Lopez
openaire +2 more sources
OBJECTIVE: To review the use of transdermal fentanyl for the treatment of moderate to severe chronic pain. The article provides background on the pharmacology and pharmacokinetics of the drug, as well as the properties of the transdermal system.
L Y, Yee, J R, Lopez
openaire +2 more sources
Seminars in Reproductive Medicine, 2001
This review summarizes the clinical studies involving the once-weekly Ortho Evra/Evra contraceptive patch. The patch delivers norelgestromin (NGMN), 150 microg, and ethinyl estradiol (EE), 20 microg, daily to the systemic circulation. The contraceptive patch provided ovulation suppression and cycle control similar to that of oral norgestimate 250 ...
G W, Creasy, L S, Abrams, A C, Fisher
openaire +2 more sources
This review summarizes the clinical studies involving the once-weekly Ortho Evra/Evra contraceptive patch. The patch delivers norelgestromin (NGMN), 150 microg, and ethinyl estradiol (EE), 20 microg, daily to the systemic circulation. The contraceptive patch provided ovulation suppression and cycle control similar to that of oral norgestimate 250 ...
G W, Creasy, L S, Abrams, A C, Fisher
openaire +2 more sources
Neonatal Network, 2000
TO PROVIDE OPTIMAL CARE FOR selected neonates in a neonatal intensive care unit (NICU), opioid sedation and analgesia may be required. Not only is this a caring approach, but there is mounting evidence that biochemical and physiologic stress responses to acute disease may directly influence the neonate’s outcome.1Opioid analgesia and sedation decrease ...
openaire +2 more sources
TO PROVIDE OPTIMAL CARE FOR selected neonates in a neonatal intensive care unit (NICU), opioid sedation and analgesia may be required. Not only is this a caring approach, but there is mounting evidence that biochemical and physiologic stress responses to acute disease may directly influence the neonate’s outcome.1Opioid analgesia and sedation decrease ...
openaire +2 more sources
Microneedles and transdermal applications
Expert Opinion on Drug Delivery, 2006With the limitations of oral drug delivery and the pain and needle phobias associated with traditional injections, drug delivery research has focused on the transdermal delivery route. A formidable barrier to transdermal drug delivery is the stratum corneum, the superficial layer of the skin.
Raja K, Sivamani +2 more
openaire +2 more sources
Biochemical Society Transactions, 1989
The transdermal delivery of peptide drugs, though ill-favoured by their hydrophilicity and high molecular mass, would seem very attractive from the pharmacotherapeutical and patient compliance point of view. In some cases, effective transdermal dosing has been achieved in vivo, especially with the aid of iontophoresis.
H E, Bodde, J C, Verhoef, M, Ponec
openaire +2 more sources
The transdermal delivery of peptide drugs, though ill-favoured by their hydrophilicity and high molecular mass, would seem very attractive from the pharmacotherapeutical and patient compliance point of view. In some cases, effective transdermal dosing has been achieved in vivo, especially with the aid of iontophoresis.
H E, Bodde, J C, Verhoef, M, Ponec
openaire +2 more sources
Transdermal scopolamine in drooling
Journal of Intellectual Disability Research, 1988ABSTRACT. The effect of oral anticholinergic drugs has been limited in the treatment of drooling. Transdermal scopolamine (1.5 mg/2.5 cm2) offers advantages. One single application is considered to render a stable serum concentration for 3 days. A distinct reduction of basal salivation was demonstrated in an open trial of six healthy volunteers ...
E, Brodtkorb +5 more
openaire +2 more sources